[Form 4] NeuroOne Medical Technologies Corporation Insider Trading Activity

Rhea-AI Filing Summary

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) filed a Current Report on Form 8-K disclosing the formal voting results from its 16 June 2025 Annual Meeting of Shareholders.

• Election of directors: All six nominees—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins and Dina Katabi—were re-elected, each receiving roughly 1.32–1.34 million votes FOR versus 63–73 thousand AGAINST; 743,285 broker non-votes were recorded.
• Auditor ratification: Ernst & Young LLP was confirmed for fiscal 2025 with 2,072,684 FOR, 57,547 AGAINST and 147 ABSTAIN.
• Say-on-pay (advisory): Executive compensation passed (1,312,697 FOR; 78,221 AGAINST; 6,203 ABSTAIN).
• Say-on-pay frequency: Shareholders favored an annual vote (827,809 one-year vs. 562,965 three-year).
• Adjournment authority: The option to adjourn, if necessary, also passed (2,036,703 FOR; 84,719 AGAINST; 18,984 ABSTAIN).

The filing is procedural, reinforces existing governance structures and contains no new financial, operational or strategic disclosures likely to affect the company’s near-term outlook.

Insights

Corporate Governance Analyst

TL;DR: Routine AGM outcomes; board, auditor and pay package all comfortably approved.

Shareholder support exceeded 90% on every director and auditor proposal, signaling continued confidence in the board and management team. The move to an annual say-on-pay cadence aligns with ISS and Glass Lewis best-practice recommendations, potentially improving ongoing engagement with investors. Because the meeting produced no policy changes, capital allocation shifts or leadership turnover, the disclosure is largely procedural and not expected to move valuation multiples or risk perceptions.

Portfolio Manager

TL;DR: Governance status quo preserved; no immediate portfolio action required.

The decisive re-election of directors and ratification of EY eliminate near-term governance overhangs. Vote tallies reveal modest but not concerning dissent on compensation (≈5.6% AGAINST), within normal biotech small-cap ranges. While positive for continuity, the absence of financial guidance, pipeline updates or strategic transactions means the event is neutral from a fundamental and catalyst perspective. Positions in CYCN can be maintained; performance drivers remain clinical milestones rather than governance events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Christianson Mark

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Business Development Director

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		F		253	D	$0.678	261,238	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24, Power of Attorney, is attached.

	/s/ Emily Johns, by Power of Attorney	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.